February 27, 2017Blood Advances105 citationsOpen Access
Cardiac and renal complications of carfilzomib in patients with multiple myeloma
Key Points
Key points are not available for this paper at this time.
Abstract
Key Points Carfilzomib is associated with reversible cardiotoxicity in 12% of consecutive myeloma patients. Transient renal toxicity is common, but carfilzomib may improve renal function in myeloma-related renal impairment.